Related Experiment Video
Updated: May 11, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Salvage CT-guided transgluteal cryoablation for locally recurrent prostate cancer: initial experiences
Francois Cornelis1, Marion Havez, Yann Le Bras
1Department of Radiology, Pellegrin Hospital, Place Amélie Raba Léon, 33076 Bordeaux, France. francois.cornelis@chu-bordeaux.fr
Abstract:
Technical feasibility of a computed tomography (CT)-guided transgluteal approach for salvage cryoablation of inoperable locally recurrent prostate cancer was evaluated retrospectively. Five procedures were performed under general anesthesia in five patients previously treated with radiation therapy. Median age was 64 years, and average pretreatment prostate-specific antigen (PSA) level was 2.77 ng/dL (range, 0.56-4.23 ng/dL). Each cryoablation procedure was completed in one session. No complications were reported. Mean 3-month and 6-month PSA levels were 0.35 ng/dL (range, 0.16-0.54 ng/dL) and 0.51 ng/dL (range, 0.09-0.94 ng/dL), respectively, representing mean decreases of 84% (range, 71%-92%) and 81% (range, 78%-84%), respectively. Salvage CT-guided transgluteal cryoablation of the prostate therefore appears technically feasible.

